Cargando…
The current landscape of the FDA approved companion diagnostics
Predictive biomarker is an important element in the realization of precision medicine and with the introduction of the drug-diagnostic codevelopment model, the number of regulatory approved companion diagnostics (CDx) have steadily increased. This short perspective is based on an analysis of the FDA...
Autor principal: | Jørgensen, Jan Trøst |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957094/ https://www.ncbi.nlm.nih.gov/pubmed/33714919 http://dx.doi.org/10.1016/j.tranon.2021.101063 |
Ejemplares similares
-
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
por: Twomey, Julianne D., et al.
Publicado: (2021) -
First vaccine approval under the FDA Animal Rule
por: Beasley, David W C, et al.
Publicado: (2016) -
An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023) -
The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.
por: Olivier, Timothée, et al.
Publicado: (2022) -
The FDA-Approved Essure Device Counseling Order Fails to Promote Patient Empowerment
por: Gunn, Christine M., et al.
Publicado: (2019)